Search - tctmd.com

Displaying 341 - 360 of 468

Sort: Relevancy | Date

News Daily News

APPOSITION II Published: Self-Expanding Stent Performs Well in STEMI Patients

December 17, 2012

News Conference News TCT 2012

COMPARE II: Biolimus-Eluting Stent Rivals Everolimus-Eluting Stent in All-Comers Trial

November 02, 2012

Presentation TCT 2012

RESET 2-Year: A Prospective, Randomized Trial of Everolimus-Eluting vs. Sirolimus-Eluting Stents

Presenter: Ken Kozuma

October 25, 2012

Presentation TCT 2012

Long-Term Results of Bifurcation Stenting with Everolimus-eluting vs. Sirolimus-eluting Stents: The SEA-CORP BC Trials

Presenter: Francesco Burzotta

October 25, 2012

Presentation TCT 2012

SORT OUT IV 3-Year: A Prospective, Randomized Trial of Everolimus-Eluting vs. Sirolimus-Eluting Stents

Presenter: Lisette Okkels Jensen

October 25, 2012

Presentation TCT 2012

LEADERS 5-Year: A Prospective, Randomized Trial of Bioabsorbable Polymer-based Biolimus-Eluting vs. Sirolimus-Eluting Stents

Presenter: Patrick Serruys

October 25, 2012

News Conference News TCT 2012

Positive Long-Term Results from LEADERS, BioFreedom FIM, ISAR-TEST 5

October 24, 2012

News Conference News TCT 2012

Experts Discuss Need for Development of Next-Generation DES, Insights from Pathology

October 24, 2012

Presentation TCT 2012

TCT-44. LEADERS: 5-Year Follow-up from a Prospective, Randomized Trial of Biolimus A9-eluting Stents with a Biodegradable Polymer vs. Sirolimus-eluting Stents with a Durable...

Presenter: Patrick Serruys

October 23, 2012

Presentation TCT 2012

TCT-41. The Impact of Left Main Disease on Long-term Clinical Outcomes Among Patients Treated with the Unrestricted Use of Everolimus-Eluting, Sirolimus-Eluting, and...

Presenter: Giulio Stefanini

October 23, 2012

Presentation TCT 2012

TARGET I: A Prospective, Randomized Trial of a Biodegradable Polymer-based Sirolimus-Eluting Stent vs an Everolimus-Eluting Stent (MicroPort)

Presenter: Run-Lin Gao

October 23, 2012

Presentation TCT 2012

Sirolimus-Eluting Stent (Svelte Medical) Program Update

Presenter: Mark Webster

October 23, 2012

News Industry News

Micell Technologies Announces Positive Data from Clinical Studies of MiStent SES

October 23, 2012

News Conference News TCT 2012

Large Study Finds Comparable 8-Month TVF for PES, SES

October 23, 2012

Presentation TCT 2012

DESSOLVE II: A Prospective, Randomized Trial of a Biodegradable Polymer-based Sirolimus-Eluting Stent vs a Zotarolimus-Eluting Stent (Micell)

Presenter: David Kandzari

October 23, 2012

News Conference News TCT 2012

Several Trials Highlight DES Comparisons

October 22, 2012

Presentation TCT 2012

J-DESSERT: A Prospective, Randomized Trial of Paclitaxel-Eluting vs. Sirolimus-Eluting Stents in Patients with and without Diabetes

Presenter: Masato Nakamura

October 22, 2012

News Industry News

OrbusNeich’s COMBO Dual Therapy Stent™ to be Featured in Multiple Clinical Data Presentations Next Week at TCT 2012(2)

October 16, 2012

News Industry News

OrbusNeich’s COMBO Dual Therapy Stent™ to be Featured in Multiple Clinical Data Presentations Next Week at TCT 2012

October 16, 2012

News Daily News

Stent Fractures Persist Among Newer-Generation Devices

Jason Kahn

October 02, 2012

Advertisement

APPOSITION II Published: Self-Expanding Stent Performs Well in STEMI Patients

COMPARE II: Biolimus-Eluting Stent Rivals Everolimus-Eluting Stent in All-Comers Trial

RESET 2-Year: A Prospective, Randomized Trial of Everolimus-Eluting vs. Sirolimus-Eluting Stents

Long-Term Results of Bifurcation Stenting with Everolimus-eluting vs. Sirolimus-eluting Stents: The SEA-CORP BC Trials

SORT OUT IV 3-Year: A Prospective, Randomized Trial of Everolimus-Eluting vs. Sirolimus-Eluting Stents

LEADERS 5-Year: A Prospective, Randomized Trial of Bioabsorbable Polymer-based Biolimus-Eluting vs. Sirolimus-Eluting Stents

Positive Long-Term Results from LEADERS, BioFreedom FIM, ISAR-TEST 5

Experts Discuss Need for Development of Next-Generation DES, Insights from Pathology

TCT-44. LEADERS: 5-Year Follow-up from a Prospective, Randomized Trial of Biolimus A9-eluting Stents with a Biodegradable Polymer vs. Sirolimus-eluting Stents with a Durable...

TCT-41. The Impact of Left Main Disease on Long-term Clinical Outcomes Among Patients Treated with the Unrestricted Use of Everolimus-Eluting, Sirolimus-Eluting, and...

TARGET I: A Prospective, Randomized Trial of a Biodegradable Polymer-based Sirolimus-Eluting Stent vs an Everolimus-Eluting Stent (MicroPort)

Sirolimus-Eluting Stent (Svelte Medical) Program Update

Micell Technologies Announces Positive Data from Clinical Studies of MiStent SES

Large Study Finds Comparable 8-Month TVF for PES, SES

DESSOLVE II: A Prospective, Randomized Trial of a Biodegradable Polymer-based Sirolimus-Eluting Stent vs a Zotarolimus-Eluting Stent (Micell)

Several Trials Highlight DES Comparisons

J-DESSERT: A Prospective, Randomized Trial of Paclitaxel-Eluting vs. Sirolimus-Eluting Stents in Patients with and without Diabetes

OrbusNeich’s COMBO Dual Therapy Stent™ to be Featured in Multiple Clinical Data Presentations Next Week at TCT 2012(2)

OrbusNeich’s COMBO Dual Therapy Stent™ to be Featured in Multiple Clinical Data Presentations Next Week at TCT 2012

Stent Fractures Persist Among Newer-Generation Devices

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content